Janux Therapeutics Ownership | Who Owns Janux Therapeutics?


OverviewForecastRevenueFinancialsChart

Janux Therapeutics Ownership Summary


Janux Therapeutics is owned by 83.49% institutional investors, 7.75% insiders, and 8.76% retail investors. Ra capital management is the largest institutional shareholder, holding 18.69% of JANX shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.18% of its assets in Janux Therapeutics shares.

JANX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockJanux Therapeutics83.49%7.75%8.76%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management9.17M18.69%$383.95M
Fmr7.78M15.86%$325.80M
Orbimed advisors2.98M6.08%$124.82M
Blackrock2.34M4.78%$98.19M
Adage capital partners gp2.33M4.75%$97.52M
Janus henderson group1.80M3.67%$75.39M
Paradigm biocapital advisors lp1.56M3.19%$65.53M
Vanguard group1.56M3.18%$65.42M
Ecor1 capital1.47M3.00%$61.57M
State street1.40M2.86%$58.70M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ra capital management9.17M5.08%$383.95M
Cormorant asset management, lp1.05M2.54%$43.98M
Logos global management lp750.00K2.53%$31.42M
Paradigm biocapital advisors lp1.56M2.51%$65.53M
Orbimed advisors2.98M2.48%$124.82M
Vestal point capital, lp725.00K2.26%$30.37M
Ecor1 capital1.47M1.88%$61.57M
Avidity partners management lp840.22K1.50%$35.20M
Ratan capital management lp105.76K1.34%$4.43M
Stempoint capital lp92.95K1.14%$3.89M

Top Buyers

HolderShares% AssetsChange
Paradigm biocapital advisors lp1.56M2.51%1.56M
Ecor1 capital1.47M1.88%1.47M
State street1.40M0.00%1.00M
Vestal point capital, lp725.00K2.26%725.00K
Blackrock2.34M0.00%650.02K

Top Sellers

HolderShares% AssetsChange
Orbimed advisors2.98M2.48%-1.30M
Rtw investments, lp---1.00M
Adage capital partners gp2.33M0.18%-447.78K
Bvf inc/il---441.53K
Samlyn capital---324.70K

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp1.56M2.51%1.56M$65.53M
Ecor1 capital1.47M1.88%1.47M$61.57M
Vestal point capital, lp725.00K2.26%725.00K$30.37M
Point72 asset management136.43K0.01%136.43K$5.72M
Ensign peak advisors133.00K0.01%133.00K$5.57M

Sold Out

HolderChange
Abich financial wealth management-20.00
Pacer advisors-439.00
Metropolitan life insurance co/ny-1.00K
Entrypoint capital-1.65K
Bayesian capital management, lp-5.60K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20241642.50%45,609,3962.07%831.24%88-20.00%4845.45%
Jun 30, 202415928.23%44,686,1205.66%910.99%10926.74%3317.86%
Mar 31, 202412487.88%42,293,77126.24%961.79%86109.76%28154.55%
Dec 31, 20236611.86%33,501,724-4.59%731.04%4128.13%11-31.25%
Sep 30, 2023593.51%35,112,15314.57%831.56%326.67%1614.29%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S1.66M3.18%9.56K
Fidelity Growth Compy Commingled Pl O1.65M3.16%20.65K
Fidelity Growth Company Fund1.23M2.36%-2.62K
Vanguard Total Stock Mkt Idx Inv1.00M1.92%1.61K
SPDR® S&P Biotech ETF724.52K1.39%8.02K
iShares Russell 2000 ETF722.59K1.38%-1.62K
Fidelity Select Health Care650.00K1.25%-
Fidelity Small Cap Growth644.64K1.24%-1.69K
Janus Henderson Global Life Sciences D434.28K0.83%5.30K
Fidelity Advisor Health Care I428.00K0.82%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 03, 2024Campbell David Alan President and CEOSell$1.00M
Nov 25, 2024Campbell David Alan President and CEOSell$940.23K
Nov 25, 2024Campbell David Alan President and CEOSell$349.65K
Oct 28, 2024Campbell David Alan President and CEOSell$598.91K
Oct 28, 2024Campbell David Alan President and CEOSell$739.65K

Insider Transactions Trends


DateBuySell
2024 Q4122
2024 Q3-33
2024 Q2-8
2024 Q11-
2023 Q43-

JANX Ownership FAQ


Who Owns Janux Therapeutics?

Janux Therapeutics shareholders are primarily institutional investors at 83.49%, followed by 7.75% insiders and 8.76% retail investors. The average institutional ownership in Janux Therapeutics's industry, Biotech Stocks , is 47.04%, which Janux Therapeutics exceeds.

Who owns the most shares of Janux Therapeutics?

Janux Therapeutics’s largest shareholders are Ra capital management (9.17M shares, 18.69%), Fmr (7.78M shares, 15.86%), and Orbimed advisors (2.98M shares, 6.08%). Together, they hold 40.62% of Janux Therapeutics’s total shares outstanding.

Does Blackrock own Janux Therapeutics?

Yes, BlackRock owns 4.78% of Janux Therapeutics, totaling 2.34M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 98.19M$. In the last quarter, BlackRock increased its holdings by 650.02K shares, a 38.37% change.

Who is Janux Therapeutics’s biggest shareholder by percentage of total assets invested?

Ra capital management is Janux Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.08% of its assets in 9.17M Janux Therapeutics shares, valued at 383.95M$.

Who is the top mutual fund holder of Janux Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Janux Therapeutics shares, with 3.18% of its total shares outstanding invested in 1.66M Janux Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools